[Prospective biochemical study of the antioxidant defense capacity in retinopathy of prematurity].
The study was carried out on 60 oxygen-treated premature infants weighed less than 2000 g (1529 +/- 302 g, x mean +/- S. D.) and on their mothers. Both the Retinopathy of Prematurity screening and the biochemical tests were started at the age of 6 weeks. According to our results, the signs of an acute oxidative stress could be seen in all 60 oxygen-treated prematures erythrocyte's glutathione redox system, independently of the presence of the retinopathy compared to prematures (n = 20) with the same gestational age but without oxygen therapy (1720 +/- 305 g, mean +/- S.D.). The concentrations of free sulfhydril groups in the plasma, and the blood selenium levels were significantly lower in the prematures suffering from moderate retinopathy (n = 5) than in the other oxygen-treated premature without retinopathy (n = 27) and with "any retinopathy" (n = 28) patients groups. The same tendency was seen in the mothers. Vitamin E treatment of "any retinopathy" infants seemed to have a positive effect against the development of Retinopathy of Prematurity. The close correlation found between the antioxidant capacity of the mothers and babies suggest that the supplementation of feeding with sulfur-containing amino acids (methionine, cysteine) during pregnancy would improve the antioxidant capacity of prematures. An antioxidant cocktail (selenium + vitamin E) given to the high-risk mothers (advanced age, smoking, pregnancy-induced hypertension) before delivery as suggested in literature might be useful in prevention of Retinopathy of Prematurity.
Papp
A
A
Szent-Györgyi Albert Orvostudományi Egyetem, Szeged, Szemészeti Klinika.
Németh
I
I
Pelle
Z
Z
Tekulics
P
P
D000975:Antioxidants / Q000378:metabolism*; D005260:Female; D005980:Glutathione Reductase / Q000378:metabolism; D006801:Humans; D006973:Hypertension; D007231:Infant, Newborn; D008297:Male; D008423:Maternal Age; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy* / Q000378:metabolism; D012178:Retinopathy of Prematurity / Q000517:prevention & control / Q000628:therapy; D012307:Risk Factors; D012643:Selenium / Q000627:therapeutic use; D012907:Smoking; D014810:Vitamin E / Q000627:therapeutic use
D000975:Antioxidants; D014810:Vitamin E; D005980:Glutathione Reductase; D012643:Selenium
Az antioxidáns védekezóképesség prospektív, biokémiai vizsgálata retinopathia preamaturorumban.